Curis/Genentech's Vismodegib Aims for Smooth Approval Path
By Trista Morrison
Tuesday, September 13, 2011
Curis Inc. could soon collect an $8 million milestone payment from partner Genentech Inc., assuming the FDA accepts the newly filed new drug application (NDA) for vismodegib (RG3616/GDC-0449) in advanced, inoperable basal cell carcinoma (BCC).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.